Role of GPRC5D in R/R MM Patients
An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.
EP: 1.Case Presentation: Clinical Decision Making in a R/R MM patient
EP: 2.Treatment Options in Late Line Relapsed/Refractory MM Patients
Now Viewing
EP: 3.Role of GPRC5D in R/R MM Patients
EP: 4.Case Presentation: Clinical Decision Making in a Patient With R/R MM
EP: 5.Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM
EP: 6.Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D Bispecific
EP: 7.Case Presentation: Clinical Decision Making for a Patient With R/R MM
EP: 8.Patient-Centric Care in R/R MM
EP: 9.Guiding Through Challenges: Insights for Caregivers of R/R MM Patients
EP: 10.APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
